There has been a great deal of renewed attention in immuno-oncology over the last decade.   Therapies for cancer are being developed, approved, and administered that can either initiate, modulate, or enhance immune response to various cancers including metastatic cancer.  This presentation will examine the advantages of using RNA measurements of the tumor micro-environment to measure not only tumor-cell expression and related systems but also the immune response (if any) to the tumor.  We will examine evidence of pan-cancer immunogenicity by utilizing RNA-Seq data from The Cancer Genome Atlas (TCGA).   From this view, we will see direct evidence that immune response can vary by cancer type and vary from other potential biomarkers of immunogenicity including tumor mutational burden.  In particular, we will examine potential applications of immune subsystem-related biomarkers with ovarian cancer in prognostic areas such as predicting event-free and overall survival.